ArticleCancer biology & therapy2021

JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy.

Govind Babu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.